These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 15857828)

  • 1. Somatostatin receptor type 5 modulates somatostatin receptor type 2 regulation of adrenocorticotropin secretion.
    Ben-Shlomo A; Wawrowsky KA; Proekt I; Wolkenfeld NM; Ren SG; Taylor J; Culler MD; Melmed S
    J Biol Chem; 2005 Jun; 280(25):24011-21. PubMed ID: 15857828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy.
    Ben-Shlomo A; Schmid H; Wawrowsky K; Pichurin O; Hubina E; Chesnokova V; Liu NA; Culler M; Melmed S
    J Clin Endocrinol Metab; 2009 Nov; 94(11):4342-50. PubMed ID: 19820006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective regulation of somatostatin receptor subtype signaling: evidence for constitutive receptor activation.
    Ben-Shlomo A; Pichurin O; Barshop NJ; Wawrowsky KA; Taylor J; Culler MD; Chesnokova V; Liu NA; Melmed S
    Mol Endocrinol; 2007 Oct; 21(10):2565-78. PubMed ID: 17609435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous srif activity and response to octreotide.
    Park C; Yang I; Woo J; Kim S; Kim J; Kim Y; Sohn S; Kim E; Lee M; Park H; Jung J; Park S
    Endocr J; 2004 Apr; 51(2):227-36. PubMed ID: 15118275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas.
    Saveanu A; Gunz G; Guillen S; Dufour H; Culler MD; Jaquet P
    Neuroendocrinology; 2006; 83(3-4):258-63. PubMed ID: 17047391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells.
    van der Hoek J; Waaijers M; van Koetsveld PM; Sprij-Mooij D; Feelders RA; Schmid HA; Schoeffter P; Hoyer D; Cervia D; Taylor JE; Culler MD; Lamberts SW; Hofland LJ
    Am J Physiol Endocrinol Metab; 2005 Aug; 289(2):E278-87. PubMed ID: 15769796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Native somatostatin sst2 and sst5 receptors functionally coupled to Gi/o-protein, but not to the serum response element in AtT-20 mouse tumour corticotrophs.
    Cervia D; Fehlmann D; Hoyer D
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Jun; 367(6):578-87. PubMed ID: 12750875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists.
    Cescato R; Schulz S; Waser B; Eltschinger V; Rivier JE; Wester HJ; Culler M; Ginj M; Liu Q; Schonbrunn A; Reubi JC
    J Nucl Med; 2006 Mar; 47(3):502-11. PubMed ID: 16513620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New medical treatments in pituitary adenomas].
    Drutel A; Caron P; Archambeaud F
    Ann Endocrinol (Paris); 2008 Sep; 69 Suppl 1():S16-28. PubMed ID: 18954854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatostatin receptor expression and patients' response to targeted medical treatment in pituitary tumors: evidences and controversies.
    Gatto F; Arvigo M; Ferone D
    J Endocrinol Invest; 2020 Nov; 43(11):1543-1553. PubMed ID: 32557353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro.
    Ibáñez-Costa A; Rivero-Cortés E; Vázquez-Borrego MC; Gahete MD; Jiménez-Reina L; Venegas-Moreno E; de la Riva A; Arráez MÁ; González-Molero I; Schmid HA; Maraver-Selfa S; Gavilán-Villarejo I; García-Arnés JA; Japón MA; Soto-Moreno A; Gálvez MA; Luque RM; Castaño JP
    J Endocrinol; 2016 Nov; 231(2):135-145. PubMed ID: 27587848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography.
    Schaer JC; Waser B; Mengod G; Reubi JC
    Int J Cancer; 1997 Mar; 70(5):530-7. PubMed ID: 9052751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell specific interaction of pasireotide: review of preclinical studies in somatotroph and corticotroph pituitary cells.
    Gatto F; Arvigo M; Amarù J; Campana C; Cocchiara F; Graziani G; Bruzzone E; Giusti M; Boschetti M; Ferone D
    Pituitary; 2019 Feb; 22(1):89-99. PubMed ID: 30483918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas.
    Saveanu A; Jaquet P; Brue T; Barlier A
    Mol Cell Endocrinol; 2008 May; 286(1-2):206-13. PubMed ID: 18241980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dimerization of GPCRs: Novel insight into the role of FLNA and SSAs regulating SST
    Treppiedi D; Marra G; Di Muro G; Catalano R; Mangili F; Esposito E; Calebiro D; Arosio M; Peverelli E; Mantovani G
    Front Endocrinol (Lausanne); 2022; 13():892668. PubMed ID: 35992099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of 17beta-estradiol on somatostatin receptor expression and inhibitory effects on growth hormone and prolactin release in rat pituitary cell cultures.
    Djordjijevic D; Zhang J; Priam M; Viollet C; Gourdji D; Kordon C; Epelbaum J
    Endocrinology; 1998 May; 139(5):2272-7. PubMed ID: 9564833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro.
    Lesche S; Lehmann D; Nagel F; Schmid HA; Schulz S
    J Clin Endocrinol Metab; 2009 Feb; 94(2):654-61. PubMed ID: 19001514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro.
    Zatelli MC; Piccin D; Tagliati F; Bottoni A; Ambrosio MR; Margutti A; Scanarini M; Bondanelli M; Culler MD; degli Uberti EC
    J Mol Endocrinol; 2005 Oct; 35(2):333-41. PubMed ID: 16216913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Homologous and heterologous in vitro regulation of pig pituitary somatostatin receptor subtypes, sst1, sst2 and sst5 mRNA.
    Luque RM; Park S; Peng XD; Delgado E; Gracia-Navarro F; Kineman RD; Malagón MM; Castaño JP
    J Mol Endocrinol; 2004 Apr; 32(2):437-48. PubMed ID: 15072550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Constitutive somatostatin receptor activity determines tonic pituitary cell response.
    Ben-Shlomo A; Zhou C; Pichurin O; Chesnokova V; Liu NA; Culler MD; Melmed S
    Mol Endocrinol; 2009 Mar; 23(3):337-48. PubMed ID: 19131507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.